MetLife MET Whole and Term Life & Endowments — Issuances
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MetLife in its filing.
Tagged under the XBRL concept us-gaap:LiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitIssuance.
The official record: MetLife’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about MetLife's whole and term life & endowments — issuances.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is MetLife's whole and term life & endowments — issuances?
- MetLife (MET) reported whole and term life & endowments — issuances of $207M in Q1 2026.
- How has MetLife's whole and term life & endowments — issuances changed year-over-year?
- MetLife's whole and term life & endowments — issuances increased by 38.9% year-over-year, from $149M to $207M.
- What is the long-term trend for MetLife's whole and term life & endowments — issuances?
- Over 4 years (2021 to 2025), MetLife's whole and term life & endowments — issuances has grown at a 31.9% compound annual growth rate (CAGR), from $208M to $630M.
- What does whole and term life & endowments — issuances mean?
- This metric tracks the new liabilities established during the period due to the issuance of new whole life, term life, or endowment policies. It is a key indicator of new business production and sales momentum within the life insurance segment. Monitoring issuances helps analysts gauge the company's ability to attract new policyholders and grow its market share.